Study Demonstrates Pine Bark Naturally Reduces Hay Fever Symptoms
HOBOKEN, N.J., June 23 /PRNewswire/ -- An estimated 60 million people in the U.S. are affected by allergic rhinitis, commonly known as hay fever, according to the American Academy of Allergy Asthma and Immunology. Hay fever is an allergic inflammation of the nasal airways that causes itching, swelling, mucus production, hives and rashes. A study published in the June 14, 2010 issue of Phytotherapy Research demonstrates PycnogenolŽ (pic-noj-en-all), an antioxidant plant extract derived from the bark of the French maritime pine tree, substantially improves the symptoms of hay fever.
"Allergic rhinitis is often mistakenly believed to be a trivial health problem, while people suffering from hay fever may disagree as they experience a dramatic impairment to their quality of life," said Dr. Malkanthi Evans Scientific Director KGK Synergize Inc., a lead researcher on the study. "This study confirmed that taking PycnogenolŽ naturally relieves eye and nasal symptoms of hay fever patients owing to lower pollen-specific antibodies, particularly for ocular and nasal distress."
In a randomized, double-blind, placebo-controlled study conducted by KGK Synergize, Inc., 60 subjects between the ages of 18 and 65 began treatment three to eight weeks prior to the onset of birch allergy season in Ontario, Canada. All subjects tested positive for birch pollen allergies, a seasonal trigger of hay fever, as determined by skin prick tests. Patients were assigned to a PycnogenolŽ group or placebo group according to a computer-generated, randomized schedule. Neither the patient, the investigator nor research staff was informed to which test order the subjects were assigned. Subjects were instructed to take either one 50 mg PycnogenolŽ tablet or one placebo tablet twice daily, once in the morning and once in the evening throughout the allergy season. Patients were allowed to use non-prescription antihistamines as needed and recorded usage and dosage in treatment journals. The study was approved by an ethical committee as well as the "Health Canada" authorities.
Blood was collected before and after treatment throughout the entire birch pollen season for the measurement of birch specific IgE antibodies. Upon recognition of a specific allergen the IgE class of antibodies stimulates the release of histamine, an inflammatory mediator responsible for the hay fever symptoms. During exposure to pollen allergic people develop higher levels of the corresponding IgE antibody, which goes along with increasing hay fever symptoms. Comparison of birch specific IgE levels from the start of the trial and the end of allergy season showed an increase of 31.9 percent in the placebo group but only 19.4 percent in the PycnogenolŽ group.
Subjects were instructed to rate nasal and eye symptoms daily by means of a self-administered questionnaire, recording values in their treatment journals. These resemble problems well known to people affected by hay fever: burning, itchy, watering or tearing eyes, redness, sneezing and stuffy, runny or itchy nose. All nasal and eye symptoms were scored with values ranging from "zero" (symptoms absent) to a maximum of "three" (severe, symptoms completely preventing normal activity). Throughout the birch pollen seasons around mid of April until end of May, the total average nasal and eye symptom score was lower in the PycnogenolŽ group than in the placebo group. A detailed analysis showed that PycnogenolŽ was more effective the earlier patients began taking the product prior to the onset of the exposure to birch pollen. The researchers speculate that a lag-time of at least five weeks prior to pollen exposure is required for PycnogenolŽ to defy hay fever symptoms. Subjects taking PycnogenolŽ seven weeks before onset of the birch season required very little non-prescription antihistamine medication (12.5%) compared with subjects taking the placebo (50%).
"For the many people seeking alternatives to conventional treatment for allergic rhinitis PycnogenolŽ may represent an effective and completely natural solution, void of any side-effects," said Evans.
Previous studies have revealed PycnogenolŽ to favorably affect patients suffering from allergies. Two earlier clinical trials showed that PycnogenolŽ improves symptoms and breathing ability of asthma patients. Asthma is likewise triggered by airborne allergens and PycnogenolŽ was demonstrated to significantly decrease leukotriene levels, an inflammatory mediator involved in asthma and hay fever alike. Human pharmacologic studies have pointed to a general anti-inflammatory potency of PycnogenolŽ.
PycnogenolŽ is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and organic acids, which offer extensive natural health benefits. The extract has been widely studied for the past 40 years and has more than 230 published studies and review articles ensuring safety and efficacy as an ingredient. Today, PycnogenolŽ is available in more than 700 dietary supplements, multi-vitamins and health products worldwide. For more information, visit www.pycnogenol.com.
About Natural Health Science, Inc.
Natural Health Science Inc. (NHS), based in Hoboken, New Jersey, is the North American distributor for PycnogenolŽ (pic-noj-en-all) brand French maritime pine bark extract on behalf of Horphag Research. PycnogenolŽ is a registered trademark of Horphag Research Ltd., Guernsey, and its applications are protected by U.S. patents #5,720,956 / #6,372,266 and other international patents. Horphag Research Ltd. Is the recipient of the 2008 Frost & Sullivan North American Health Ingredients Excellence in Research Award. NHS has the exclusive rights to market and sell PycnogenolŽ in North America and benefits from more than 40 years of scientific research assuring the safety and efficacy of PycnogenolŽ as a dietary supplement. For more information about PycnogenolŽ visit our Web site at www.pycnogenol.com.
SOURCE Natural Health Science, Inc.